Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring
- PMID: 22094306
- DOI: 10.1016/j.ejps.2011.10.022
Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring
Abstract
Therapeutic drug monitoring (TDM) of aminoglycosides has been a topic during the last thirty years. There is a tendency that - because of the once-daily regimen - TDM is considered not necessary anymore. Although once daily dosing has the potential for decreased toxicity, long-term usage can cause severe nephro- and ototoxicity. Furthermore, inadequate plasma concentrations can lead to treatment failure. This work is devoted to the development and application of the first mathematical model of aminoglycosides, which simulates in relation to the pharmacokinetics both their effects on bacteria as well as their nephrotoxicity and cochleotoxicity. Our software system is suitable for TDM. Based on theoretical considerations, a multi-compartment mathematical model in a numerical program in Matlab is derived that incorporates the antimicrobial effects of aminoglycosides, the saturable and active uptake into kidney cells, the reversible nephrotoxicity and the irreversible cochleotoxicity. Using fictitious person data, and an assumed pharmacokinetic and dynamic parameter set obtained from the literature, we simulated the drug concentrations, antibacterial effects, and toxicity over time in virtual patients to illustrate the benefits of optimized, efficacious dosage regimens that minimize (acceptable) nephro- and auditory ototoxicity. Our model confirms that extended-interval dosing seems the most appropriate to achieve this goal. By this manner, the present mathematical model contributes to an increase in our knowledge of how to obtain an optimized dosing strategy for individual patients. With the developed program, we are able to demonstrate that optimal aminoglycoside dosing still needs a sophisticated system of TDM.
Copyright © 2011 Elsevier B.V. All rights reserved.
Similar articles
-
Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.Pharmacotherapy. 2010 Jan;30(1):95-108. doi: 10.1592/phco.30.1.95. Pharmacotherapy. 2010. PMID: 20030477 Review.
-
[Level of evidence for therapeutic drug monitoring of aminoglycosides].Therapie. 2011 Jan-Feb;66(1):39-44. doi: 10.2515/therapie/2011001. Epub 2011 Apr 7. Therapie. 2011. PMID: 21466776 Review. French.
-
Extended-interval aminoglycoside administration for children: a meta-analysis.Pediatrics. 2004 Jul;114(1):e111-8. doi: 10.1542/peds.114.1.e111. Pediatrics. 2004. PMID: 15231982
-
Efficacy and safety of aminoglycosides once-a-day: experimental and clinical data.Scand J Infect Dis Suppl. 1990;74:249-57. Scand J Infect Dis Suppl. 1990. PMID: 2097713 Review.
-
Management of aminoglycosides in the intensive care unit.J Intensive Care Med. 2010 Nov-Dec;25(6):327-42. doi: 10.1177/0885066610377968. Epub 2010 Sep 13. J Intensive Care Med. 2010. PMID: 20837630
Cited by
-
Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Antimicrob Agents Chemother. 2015 Apr;59(4):2315-27. doi: 10.1128/AAC.04099-14. Epub 2015 Feb 2. Antimicrob Agents Chemother. 2015. PMID: 25645838 Free PMC article.
-
Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02307-18. doi: 10.1128/AAC.02307-18. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30833428 Free PMC article. Review.
-
Stochastic process pharmacodynamics: dose timing in neonatal gentamicin therapy as an example.AAPS J. 2015 Mar;17(2):447-56. doi: 10.1208/s12248-014-9715-3. Epub 2015 Feb 7. AAPS J. 2015. PMID: 25663652 Free PMC article.
-
The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Intensive Care Med. 2017. PMID: 28409203 Review.
-
Examining Mannitol Use in Kidney Cancer Surgery: A Cautionary Tale of Extrapolated Surgical Data.Eur Urol Focus. 2019 Nov;5(6):930-934. doi: 10.1016/j.euf.2019.09.021. Epub 2019 Oct 15. Eur Urol Focus. 2019. PMID: 31628080 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical